- Specialization
- Biotechnology
- Business
- Scientific Research
- Market
- Life Sciences
- Ecosystem
- Not applicable
- Customers
Enterprisesand 1 more customers valuesLess
- Researchers
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology
- Market
- Life Sciences
- Customers
- Enterprises, Researchers
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
Modulari-T is a preclinical biotechnology company developing in vivo cell and gene therapy platforms for oncology, autoimmunity, regenerative medicine, and other indications. It sells primarily through partnerships with cell-therapy companies, differentiating itself by building both the MARC immune-cell receptor and MoVe targeted delivery vehicle from scratch in one integrated system.
Market
Modulari-T competes in the preclinical cell-and-gene-therapy and immunotherapy market, with an initial oncology focus and stated expansion into autoimmune disease and regenerative medicine. Its core positioning is a vertically integrated in vivo cell-and-gene-therapy system: it developed both the MARC receptor and MoVe delivery vehicle from scratch, combining modular immune-cell signaling with targeted delivery across immune and non-immune cells. This differentiates it from in vivo CAR-T approaches such as Capstan’s targeted LNPs, Umoja’s VivoVec, Orna’s oRNA/LNP panCAR, Interius’s targeted delivery, and EsoBiotec’s in vivo CAR-T platform.
Primary customers are cell-therapy and biopharmaceutical companies, especially preclinical or growth-stage R&D organizations developing oncology, autoimmune, regenerative-medicine, or other cell-and-gene-therapy programs. The likely buyer is a scientific or therapeutic-development leader seeking to partner with or incorporate Modulari-T’s MARC and MoVe platforms into a development pipeline.
At a Glance
Problem
Modulari-T is addressing the limits that have kept first-generation cell therapy from reaching more patients. The company identifies oncology, autoimmunity, and inflammation as therapeutic areas where first-generation approaches either failed or never arrived, leaving patients waiting. Economically, the opportunity is to expand cell therapy beyond its current patient and indication base; the available materials do not quantify the cost of the unmet need, but they position broader access and new indications as the central value proposition. The clearest near-term use case is the company’s wholly owned uPAR-targeting oncology program, scheduled to enter IND-enabling studies in the fourth quarter of 2026.
Product / Service
Modulari-T’s core offering is an integrated cell- and gene-therapy platform built around MARCs, or Modular Actuation Receptor Complexes, and MoVes, or Modular Vectors. MARCs separate target recognition from signaling, recreate the architecture of natural immune receptors, and are designed to switch on when triggered and off when recycled. The company says the approach can improve targeting, efficacy, safety, and signal control across T cells, NK cells, B cells, regulatory T cells, and selected non-immune cells, including through logic-gated, pH-sensitive, and bispecific designs.
MoVes are re-engineered viral delivery vehicles with modular envelopes and custom promoters intended to selectively enter a broad range of immune and non-immune cells. They can deliver MARCs, gene-therapy payloads, or other partner technologies, with payloads either permanently integrated or expressed transiently. Modulari-T can use the system to build wholly owned therapeutic programs or partner its platform and assets, creating both an internal pipeline and a technology-licensing or collaboration pathway.
Market
The company competes in next-generation cell and gene therapy, particularly the effort to extend CAR-T and related immune-cell therapies into in vivo, off-the-shelf, safer, and more broadly applicable formats. Its materials contrast MARCs with conventional CARs and MoVes with traditional lentiviral and adenoviral delivery approaches. No specific competing company is identified in the available evidence; the clearest competitive reference points are these established technology classes and the broader in vivo cell-therapy field.
Modulari-T was founded in 2021, joined Y Combinator’s Winter 2023 batch, remains active, and reports a four-person team. The company says its platform has been validated across diverse cell types and modalities, and its COO reports securing more than $1 million in non-dilutive capital. The uPAR program’s planned 2026 IND-enabling work is the clearest disclosed development milestone. Revenue, commercial sales, and clinical-stage traction are not disclosed in the available materials, so the company is best characterized as a development-stage biotech rather than definitively labeled pre-revenue.
Founders & Leadership
Funding History
Y Combinator
Recent News
Modulari-T appointed Tanya E. Borsuk as CEO, while co-founder David Cotnoir-White became President and CSO. The leadership change reflects the company’s transition toward a late-stage, partnership-driven business focused on in vivo cell and gene therapies.
Modulari-T Biosciences was selected for the second cohort of Merck’s Digital Sciences Studio in Montréal, a nine-month accelerator providing mentorship, technology resources and funding. Each selected startup receives $100,000, with the program offering potential access to longer-term collaborations with Merck and other partners.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
The company does not publicly disclose product pricing or current recurring revenue. Its apparent commercialization model is to partner with cell-therapy companies around its MARC and MoVe platforms, likely through strategic collaborations or co-development agreements rather than direct consumer sales.